News|Articles|November 18, 2026

SNO 2026 Shows Lasting Responses, Ongoing Research for Safusidenib

Fact checked by: Tim Cortese, Russ Conroy

Safusidenib showed durable responses in IDH1-mutant glioma, and ongoing trials will test the agent in oligodendroglioma, after vorasidenib, and as maintenance.

At the 2026 Society for Neuro-Oncology (SNO) Annual Meeting, investigators presented 4 posters on safusidenib, an investigational oral inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) with high potency, selectivity, and blood-brain barrier permeability.1-4 One reported updated phase 2 efficacy and safety data in chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma. The other 3 described ongoing studies in grade 3 oligodendroglioma, glioma that progressed on vorasidenib (Voranigo), and astrocytoma with high-risk features.

Related to this article